Pharming Group (PHARM) Investor Day 2026 summary

Financial performance and guidance

• 2025 revenues reached $376 million, a 27% increase year-over-year, with both commercial assets exceeding prior guidance.

• RUCONEST generated $318 million in 2025 (26% growth), while Joenja delivered $58 million (29% growth), triggering a $5 million milestone payment to Novartis.

• 2026 revenue guidance is $405–$425 million, representing 8–13% growth, with Joenja and RUCONEST as key drivers.

• 2026 operating expenses are projected at $330–$335 million, mainly due to over $60 million in incremental R&D investment and $9 million in G&A cost reductions.

• Gross margin is expected to be around 90% in 2026, with available cash and future cash flows covering all pipeline and pre-launch investments.

Commercial and pipeline strategy

• Transitioned to a fast-growth biotech with two commercial assets and a late-stage pipeline, each with over $1 billion sales potential.

• RUCONEST remains a cornerstone for difficult-to-treat patients, with U.S. growth offsetting ex-U.S. market exits; Joenja is at the start of its lifecycle with multiple growth catalysts, including potential pediatric label expansion.

• Conservative 2026 guidance excludes revenues from Joenja pediatric APDS until regulatory clarity is achieved.

• Expansion into larger PIDs and CVID with leniolisib could unlock a much larger market, supported by strong clinical rationale and ongoing phase II studies.

• Enhanced capital allocation and disciplined cost management support high-growth initiatives.

Pipeline and clinical development

• Advancing two major programs: leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation and napazimone (KL1333) for mtDNA-driven mitochondrial disease.

• Two multinational phase II studies for leniolisib in PIDs/CVID with immune dysregulation are underway, with top-line data expected in H2 2026.

• Napazimone pivotal study is ongoing, with positive interim analysis and readout anticipated in 2027.

• Both programs target significant unmet needs and large addressable patient populations.

• Real-world and single-patient IND experiences support the clinical rationale for leniolisib.